Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes

Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Allen, 2018, Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study, Hepatology, 67, 1726, 10.1002/hep.29546 Lazarus, 2020, NAFLD – sounding the alarm on a silent epidemic, Nat Rev Gastroenterol Hepatol, 17, 377, 10.1038/s41575-020-0315-7 Targher, 2021, The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments, Nat Rev Gastroenterol Hepatol, 18, 599, 10.1038/s41575-021-00448-y Ampuero, 2020, Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH, J Hepatol, 73, 17, 10.1016/j.jhep.2020.02.028 Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 Adams, 2017, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases, Gut, 66, 1138, 10.1136/gutjnl-2017-313884 Byrne, 2020, NAFLD as a driver of chronic kidney disease, J Hepatol, 10.1016/j.jhep.2020.01.013 Alexander, 2019, Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from a matched cohort study of 18 million European adults, BMJ, 367, l5367, 10.1136/bmj.l5367 Zhou, 2018, Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis, Eur J Gastroenterol Hepatol, 30, 631, 10.1097/MEG.0000000000001075 Pennisi, 2022, Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis, Aliment Pharmacol Ther, 55, 604, 10.1111/apt.16763 Sanyal, 2021, NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease, N Engl J Med, 385, 1559, 10.1056/NEJMoa2029349 Shili-Masmoudi, 2020, Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease, Liver Int, 40, 581, 10.1111/liv.14301 Petta, 2021, Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease, Clin Gastroenterol Hepatol, 19, 806, 10.1016/j.cgh.2020.06.045 Mantovani, 2022, Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis, Gut, 71, 156, 10.1136/gutjnl-2020-323082 Aubert, 2022, Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus, Nephrol Dial Transplant, 37, 1125, 10.1093/ndt/gfab176 Cusi, 2022, Endocr Pract, 28, 528, 10.1016/j.eprac.2022.03.010 Sberna, 2018, Diabet Med, 35, 368, 10.1111/dme.13565 Blank, 2020, Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination, Sci Rep, 10, 18345, 10.1038/s41598-020-75227-x Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 75(3); 659–89. Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042 Cardoso, 2021, Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study, Cardiovasc Diabetol, 20, 193, 10.1186/s12933-021-01388-2 de Sousa Magalhães, 2021, Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients, Clin Res Hepatol Gastroenterol, 45, 101580, 10.1016/j.clinre.2020.11.010 Mantovani, 2021, Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 6, 903, 10.1016/S2468-1253(21)00308-3 Alon, 2022, Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis, Eur J Prev Cardiol, 29, 938, 10.1093/eurjpc/zwab212 Zhou, 2018, Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis, Hepatol Commun, 2, 376, 10.1002/hep4.1155 Villanova, 2005, Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease, Hepatology, 42, 473, 10.1002/hep.20781 Planas A, Simó-Servat O, Bañeras J, Sánchez M, García E, Ortiz ÁM, et al. Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes. Acta Diabetol, 58; 1403–12. Simó, 2019, Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study, BMJ Open Diab Res Care, 7, e000845, 10.1136/bmjdrc-2019-000845 American Diabetes Association. 2021. “2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021.” Diabetes Care 44 (Suppl. 1): S15–33. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–276. Nambi, 2010, Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study, J Am Coll Cardiol, 55, 1600, 10.1016/j.jacc.2009.11.075 Kramer, 2013, Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis, BMJ, 346, f1654, 10.1136/bmj.f1654 Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 McGlinchey, 2022, Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease, JHEP Rep, 4, 100477, 10.1016/j.jhepr.2022.100477 Boursier, 2022, Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications, Clin Gastroenterol Hepatol Talens, 2021, What do we know about inequalities in NAFLD distribution and outcomes? A scoping review, J Clin Med, 10, 5019, 10.3390/jcm10215019 Altobelli, 2020, Lifestyle risk factors for type 2 diabetes mellitus and national diabetes care systems in European countries, Nutrients, 12, 2806, 10.3390/nu12092806 Yip, 2022, Geographical similarity and differences in the burden and genetic predisposition of NAFLD, Hepatology